UK Top Court To Revisit FibroGen Patent Spat
The U.K. Supreme Court will appraise the decision to revive a FibroGen patent tied to a treatment for anemia and consider whether a planned launch of a kidney disease treatment by...To view the full article, register now.
Already a subscriber? Click here to view full article